AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17074147 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of almitrine l/d and 20 mg oryzanol 3/d
Number of subjects: 241
Study 17074147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 241
Study 17074147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antidepressant treatment)
Number of subjects: 241
Study 15447755 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 22
Study 15447755 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg plus Isosorbide-5-mononitrate 20 mg
Number of subjects: 22
Study 11588526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/day for 6 months
Number of subjects: 51
Study 11588526 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 51
Study 11588526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (subgroup of 15 subjects with low adenosine flow)
Number of subjects: 51
Study 11588526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup of 15 subjects with low adenosine flow)
Number of subjects: 51
Study 9842024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast potassium (20 mg/d from 1 week before PTCA until follow-up angiography at 4 months)
Number of subjects: 205
Study 9842024 — intervention group
Group type: COMPARATOR
Intervention: Control (no pemirolast)
Number of subjects: 205
Study 9842024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast potassium
Number of subjects: 205
Study 9842024 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study 7813732 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation for control of postoperative haemorrhage
Number of subjects: 654
Study 7813732 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for sex and primary operation)
Number of subjects: 654
Study 7813732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring reoperation
Number of subjects: 654
Study 2572372 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 7
Study 2572372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1101943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 100
Study 1101943 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study 1101943 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Cardiff Infusion apparatus for PGE2
Number of subjects: 100
Study 1101943 — intervention group
Group type: COMPARATOR
Intervention: Non-automatic techniques for PGE2 and oxytocin infusion
Number of subjects: 100
Study 31858865 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Mobilization (EM)
Number of subjects: 60
Study 31858865 — intervention group
Group type: COMPARATOR
Intervention: Standard Early Rehabilitation (SER)
Number of subjects: 60
Study 31299479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working‐Memory Training (CWMT)
Number of subjects: 34
Study 31299479 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 34
Study 28537443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PAPP-A
Number of subjects: 683
Study 28537443 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proMBP
Number of subjects: 683
Study 25262139 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty salience and God concept priming
Number of subjects: 120
Study 25262139 — intervention group
Group type: COMPARATOR
Intervention: Uncertainty salience and neutral prime
Number of subjects: 120
Study 25262139 — intervention group
Group type: COMPARATOR
Intervention: Insecurity salience and God concept priming
Number of subjects: 120
Study 25262139 — intervention group
Group type: COMPARATOR
Intervention: Insecurity salience and neutral prime
Number of subjects: 120
Study 23234618 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin plus tamsulosin
Number of subjects: 398
Study 23234618 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus tamsulosin
Number of subjects: 398
Study 21752077 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper case
Number of subjects: 3
Study 21752077 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised patient (SP) presentation
Number of subjects: 3
Study 21752077 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD presentation
Number of subjects: 3
Study 18650223 — intervention group
Group type: COMPARATOR
Intervention: Light-exposed TPN (LE)
Number of subjects: 59
Study 18650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-protected TPN (LP)
Number of subjects: 59
Study 16942429 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser preparation
Number of subjects: 40
Study 16942429 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical preparation
Number of subjects: 40
Study 15236813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning intervention focusing on risks of smoking
Number of subjects: 144
Study 15236813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning intervention focusing on feasibility of quitting
Number of subjects: 144
Study 15236813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study 11372041 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 111
Study 9227688 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiomotor cueing during motor activity
Number of subjects: 50
Study 9227688 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 50
Study 7968427 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 11
Study 7968427 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11
Study 7968427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7968427 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol and Atenolol
Number of subjects: 11
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation of retroperitoneal lymph nodes after orchidectomy
Number of subjects: 152
Study 3034795 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only after orchidectomy
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (irradiation and surveillance)
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for relapsed patients
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of embryonal carcinoma and presence of teratocarcinoma
Number of subjects: 152
Study 3034795 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum concentrations of tumour markers before orchidectomy
Number of subjects: 152
Study 31344303 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons seen first in their work shift
Number of subjects: 0
Study 31344303 — intervention group
Group type: COMPARATOR
Intervention: Surgeons seen toward the end of their work shift
Number of subjects: 0
Study 31344303 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional patient appointment in the doctors' work shift
Number of subjects: 0
Study 28158579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-paclitaxel (10 mg/kg bevacizumab on Days 1 and 15, paclitaxel 90 mg/m2 on Days 1, 8, and 15, repeated every 4 weeks)
Number of subjects: 54
Study 28158579 — intervention group
Group type: COMPARATOR
Intervention: Placebo-paclitaxel (placebo on Days 1 and 15, paclitaxel 90 mg/m2 on Days 1, 8, and 15, repeated every 4 weeks)
Number of subjects: 54
Study 28158579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-paclitaxel
Number of subjects: 54
Study 25554360 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (0.45g nitrate; 5mM) for three days
Number of subjects: 6
Study 25554360 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's (control)
Number of subjects: 6
Study 23263998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment group
Number of subjects: 64
Study 23263998 — intervention group
Group type: COMPARATOR
Intervention: Control group (eccentric exercises)
Number of subjects: 64
Study 21164065 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg i.v. ibuprofen (infused over five to seven minutes)
Number of subjects: 12
Study 21164065 — intervention group
Group type: COMPARATOR
Intervention: 800 mg oral ibuprofen with concomitant i.v. placebo (0.9% sodium chloride injection)
Number of subjects: 12
Study 21164065 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ibuprofen
Number of subjects: 12
Study 18640378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BBR (90 mg/[kg d], oral) with SIMVA (6 mg/[kg d], oral)
Number of subjects: 63
Study 18640378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BBR with SIMVA
Number of subjects: 63
Study 18640378 — intervention group
Group type: COMPARATOR
Intervention: SIMVA (6 mg/[kg d], oral)
Number of subjects: 63
Study 16522699 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg) with 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 1416
Study 16522699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1416
Study 12667032 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics, angiotensin II receptor blockers, ACE inhibitors
Number of subjects: 0
Study 12667032 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers and calcium-channel blockers
Number of subjects: 0
Study 12667032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10814774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 36
Study 10814774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 36
Study 10814774 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 36
Study 10814774 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective depressive symptoms
Number of subjects: 36
Study 10814774 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 36
Study 9101936 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (n = 35)
Number of subjects: 67
Study 9101936 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (n = 27)
Number of subjects: 67
Study 9101936 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal carcinomatosis (PC) (n = 5)
Number of subjects: 67
Study 1654240 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant human alpha-interferon (alpha-2a) thrice weekly for eight weeks
Number of subjects: 49
Study 1654240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6137646 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral attenuated bovine rotavirus vaccine strain RIT 4237
Number of subjects: 36
Study 26792391 — intervention group
Group type: EXPERIMENTAL
Intervention: PREFER strategy (person-centred integrated Palliative advanced homecaRE and heart FailurE caRe)
Number of subjects: 0
Study 26792391 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 29924029 — intervention group
Group type: EXPERIMENTAL
Intervention: Real VR group (n=12)
Number of subjects: 23
Study 29924029 — intervention group
Group type: COMPARATOR
Intervention: Sham VR group (n=11)
Number of subjects: 23
Study 29924029 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 23
Study 26802980 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on a continuum from mental health to mental illness
Number of subjects: 1679
Study 26802980 — intervention group
Group type: COMPARATOR
Intervention: Information on a strict dichotomy of mental health and mental illness
Number of subjects: 1679
Study 26802980 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 1679
Study 24593170 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every other week plus methotrexate
Number of subjects: 204
Study 24593170 — intervention group
Group type: COMPARATOR
Intervention: CZP 400 mg every 4 weeks plus methotrexate
Number of subjects: 204
Study 22884107 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (cIMT) measured using B-mode ultrasound at EDIC year 12
Number of subjects: 889
Study 22884107 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure adjustment
Number of subjects: 889
Study 22884107 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of DM
Number of subjects: 889
Study 20807469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Management plus Cognitive Behavioural Approach (AM+CBA)
Number of subjects: 701
Study 20807469 — intervention group
Group type: COMPARATOR
Intervention: Active Management (AM)
Number of subjects: 701
Study 17593406 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitestrips (WS) - 6% hydrogen peroxide gel, applied twice a day for 30 min
Number of subjects: 47
Study 17593406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivadent Vivastyle (VS) - 10% carbamide peroxide gel, worn for 60 min once a day
Number of subjects: 47
Study 17593406 — intervention group
Group type: COMPARATOR
Intervention: Both WS and VS
Number of subjects: 47
Study 11426357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia (TEA)
Number of subjects: 41
Study 11426357 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block (PVB)
Number of subjects: 41
Study 9249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate 8% sevoflurane in 70% nitrous oxide (HS)
Number of subjects: 46
Study 9249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental sevoflurane in 70% nitrous oxide (GS)
Number of subjects: 46
Study 9249106 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental halothane in 70% nitrous oxide (HAL)
Number of subjects: 46
Study 8297448 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (Group I)
Number of subjects: 207
Study 8297448 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium magnesium aspartate (Inzolen, Group II)
Number of subjects: 207
Study 8297448 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 207
Study 3105906 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (d‐Ser‐[TBU]6 LHRH ethylamide) prescribed in two different dosage schedules to twenty men and in a single dosage schedule to eight women
Number of subjects: 48
Study 3105906 — intervention group
Group type: COMPARATOR
Intervention: Control group (ten male controls and nine female controls)
Number of subjects: 48
Study 30287704 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual Distraction (AVD)
Number of subjects: 400
Study 30287704 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tell Show Do (TSD) and Audiovisual Distraction (AVD)
Number of subjects: 400
Study 30287704 — intervention group
Group type: COMPARATOR
Intervention: Tell Show Do (TSD)
Number of subjects: 400
Study 28159816 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-grade systolic BP measurement
Number of subjects: 275
Study 28159816 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine, research-grade, and daytime ambulatory systolic BP
Number of subjects: 275
Study 26219696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound corticomedullary strain
Number of subjects: 45
Study 26219696 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler end‐diastolic velocity (EDV)
Number of subjects: 45
Study 26219696 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler peak systolic velocity (PSV)
Number of subjects: 45
Study 26219696 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler resistive index (RI)
Number of subjects: 45
Study 26219696 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of transplantation
Number of subjects: 45
Study 24152375 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU Vitamin D₂ (ergocalciferol)
Number of subjects: 342
Study 24152375 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU Vitamin D₃ (cholecalciferol)
Number of subjects: 342
Study 24152375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 24152375 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 342
Study 21918593 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 6
Study 21918593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (80 mg/day)
Number of subjects: 6
Study 19180720 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDI assessment
Number of subjects: 174
Study 17006995 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna tablet (180 mg)
Number of subjects: 134
Study 17006995 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate solution (95 mL)
Number of subjects: 134
Study 14586240 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of stoma (mean delay of 10.0 +/- 0.8 days after initial procedure)
Number of subjects: 39
Study 14586240 — intervention group
Group type: COMPARATOR
Intervention: Late closure of stoma (mean delay of 11.4 +/- 3.7 weeks)
Number of subjects: 39
Study 14586240 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of stoma
Number of subjects: 39
Study 14586240 — intervention group
Group type: COMPARATOR
Intervention: Late closure of stoma
Number of subjects: 39
Study 10781196 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Havrix(R) vaccine, 720 EL.U. at time 0 and 6 months
Number of subjects: 45
Study 10781196 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Havrix(R) vaccine
Number of subjects: 45
Study 10781196 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Havrix(R) vaccine, 720 EL.U. at time 0 and 6 months
Number of subjects: 45
Study 10781196 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Havrix(R) vaccine
Number of subjects: 45
Study 8973771 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Co.Q10)
Number of subjects: 61
Study 8973771 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 61
Study 8973771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 1591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) after morphine (4 mg/70 kg)
Number of subjects: 5
Study 1591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) after morphine (8 mg/70 kg)
Number of subjects: 5
Study 1591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) after morphine (16 mg/70 kg)
Number of subjects: 5
Study 1591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit Symbol Substitution Test performance
Number of subjects: 5
Study 1591977 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 5
Study 31674641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Teriparatide (40-μg daily) + Denosumab (60 mg)
Number of subjects: 60
Study 31674641 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Teriparatide (20-μg daily) + Denosumab (60 mg)
Number of subjects: 60
Study 29524027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro XT Varnish (CXT)
Number of subjects: 56
Study 29524027 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP FAST (FJ)
Number of subjects: 56
Study 27003948 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of a computer‐based Stroop task (mental fatigue)
Number of subjects: 20
Study 27003948 — intervention group
Group type: COMPARATOR
Intervention: 30‐min emotionally neutral documentary (control)
Number of subjects: 20
Study 24495364 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (15-30 minutes, three times per week for the past 6 months)
Number of subjects: 160
Study 24495364 — intervention group
Group type: COMPARATOR
Intervention: Not exercising regularly for the past 12 months (control group)
Number of subjects: 160
Study 24495364 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (active group)
Number of subjects: 160
Study 24495364 — intervention group
Group type: COMPARATOR
Intervention: Not exercising regularly (control group)
Number of subjects: 160
Study 21316972 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 66
Study 21316972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 66
Study 21316972 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 66
Study 20858609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty and Stenting (CAS)
Number of subjects: 0
Study 20858609 — intervention group
Group type: COMPARATOR
Intervention: Carotid Surgery
Number of subjects: 0
Study 20858609 — intervention group
Group type: COMPARATOR
Intervention: Medical Therapy Alone
Number of subjects: 0
Study 19022005 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteosynthesis (transsternal or peristernal wiring; n = 440)
Number of subjects: 815
Study 19022005 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis with additional lateral reinforcement (Robicsek; n = 375)
Number of subjects: 815
Study 16569929 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 4.2% injected as a bolus (rapid infusion)
Number of subjects: 29
Study 16569929 — intervention group
Group type: COMPARATOR
Intervention: NaHCO3 4.2% administered over a 30-min period (slow infusion)
Number of subjects: 29
Study 16569929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rapid and slow infusion)
Number of subjects: 29
Study 14524580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HD group)
Number of subjects: 17
Study 14524580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 14524580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study 10739167 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 ultrarapid metabolizers
Number of subjects: 976